DETECTION OF CIRCULATING ANTIGENS IN PATIENTS WITH ACTIVE SCHISTOSOMA-HAEMATOBIUM INFECTION

Citation
Mm. Hassan et al., DETECTION OF CIRCULATING ANTIGENS IN PATIENTS WITH ACTIVE SCHISTOSOMA-HAEMATOBIUM INFECTION, The American journal of tropical medicine and hygiene, 59(2), 1998, pp. 295-301
Citations number
42
Categorie Soggetti
Public, Environmental & Occupation Heath","Tropical Medicine
ISSN journal
00029637
Volume
59
Issue
2
Year of publication
1998
Pages
295 - 301
Database
ISI
SICI code
0002-9637(1998)59:2<295:DOCAIP>2.0.ZU;2-2
Abstract
An antigen-capture ELISA using monoclonal antibody (MAb) 128C3/3/21 wa s used to detect circulating parasite-derived antigens in the sera of patients actively infected with Schistosoma haematobium (31 males and four females, 5-25 years of age). The assay had a sensitivity of 100% (35 of 35 patients with antigen levels > 80 ng/ml) and a specificity > 99%. We used this ELISA to monitor antigenemia before treatment and o ne, three, and six months after treatment with a single oral dose of p raziquantel (PZQ) (60 mg/kg in 20 patients or 40 mg/kg in 15 patients) and compared our findings with those indicated by other measures of d isease progression. Circulating antigen levels decreased drastically a fter PZQ treatment (P < 0.001), with a significantly higher decrease o ccurring after treatment with 60 mg/kg than with 40 mg/kg. Although th e mean antigen level was still significantly reduced (P < 0.001) at si x months after treatment, 16 patients remained antigen-positive after six months, and nine had increased levels of antigenemia, reflecting r einfection in six patients and persistence of infection in another. We observed a correlation (r = 0.6, P < 0.01) between the level of circu lating antigen and the intensity of infection as measured by egg count . We also found a direct relationship (P < 0.001) between antigen leve l and the severity of the disease as monitored by ultrasonography. We conclude that our ELISA may be a useful adjunct to other methods, such as ultrasonography, for monitoring the course of S. haematobium infec tion and treatment.